9P - Systematic determination of EGFR mutation (m) and immunohistochemistry (IHC) of ALK translocation (t) status in patients (p) with newly non small ce...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Santiago Ponce Aix
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors S. Ponce Aix1, J. Zugazagoitia2, M. Blazquez Arroyo1, G. Ruiz Ares1, J.A. Nuñez Sobrino1, L.C. Iglesias Docampo1, R.A. Manneh Kopp1, R.M. García Martín3, J.L. Rodriguez Peralto3, A.B. Enguita Valls3
  • 1Servicio De Oncologia Medica, University Hosptial 12 De Octubre Medical oncology, 28041 - Madrid/ES
  • 2Medical Oncology, Hospital 12 Octubre. Universidad Complutense, 28041 - Madrid/ES
  • 3Servicio Anatomia Patológica, University Hosptial 12 De Octubre Medical oncology, 28041 - Madrid/ES

Abstract

Detection of EGFR m. p. is done in a routine way. Also detection of ALK t. has become an important issue for therapeutic decision making in NSCLC. Which is the best technic to broad test of ALK t. remain unclear. We implemented a systematic determination of EGFR m. and ALK t. status to asses feasibility and accuracy in a clinical setting.